Log in to save activitiesYour saved activities will show here so that you can easily access them whenever you're ready. Log in hereCME & EducationLog in to keep track of your credits.
Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
Early Disease Considerations in HER2-Positive Breast Cancer CME / ABIM MOC / CENew treatments can improve the survival outcomes for women with HER2-positive breast cancer. These presentations highlight the management of early HER2-positive breast cancer.
Special Topics in HER2-Positive Breast CancerCME / ABIM MOC / CETop breast cancer experts cover the latest data on brain metastases in breast cancer, HER2-low breast cancer and HER2 testing.
Medscape Education Oncology, December 2022
Special Topics in HR-Positive Breast CancerCME / ABIM MOC / CEDid you know that approximately 65% to 70% of all breast cancers express hormone receptors in the absence of HER2 amplification?
Breast cancer is the most common cancer among women in the United States, accounting for nearly 1 of every 3 cancers diagnosed. Despite the overall decline in breast cancer mortality over the past decade, more than 40,000 deaths will be attributed to the disease in 2007 alone. Tremendous strides are made regularly in the treatment of both hormone-positive and hormone-negative disease, as well as for patients with specific tumor subtypes (eg, HER2 overexpressing tumors), posing a challenge to the clinician who must stay up to date on the most recent advances in breast cancer therapy.
